Epigenetic Reader Domain

Shop By

31 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Bromodomain inhibitor

    BET-IN-1 is a bromodomain inhibitor extracted from patent WO/2013024104A1, compound example 2, has a plC50 in the range 6.0 - 7.0. IC50 value: 6.0 - 7.0 (plC50) Target: bromodomain
  2. CBP/EP300 Inhibitor

    GNE-272 is a potent and selective in vivo probe for the bromodomains of CBP/EP300 with IC50 values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively.
  3. CBP/p300 bromodomain inhibitor

    I-CBP112 is a highly potent and selective p300/CBP bromodomain inhibitor (IC50 ~0.14-0.17 uM for CBP and ~0.625 uM for p300).
  4. SMARCA bromodomains probe

    PFI-3 is a selective chemical probe for SMARCA bromodomains.
  5. BET inhibitor

    GSK1324726A (I-BET726) is a novel, potent, and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50= 41 nM), BRD3 (IC50= 31 nM), and BRD4 (IC50= 22 nM).
  6. MBT Domain (L3MBTL1) Inhibitor

    UNC 926 is a methyl lysine reader domain inhibitor.
  7. BAZ2 bromodomain inhibitor

    BAZ2-ICR is an excellent chemical probe for functional studies of the BAZ2 bromodomains in vitro and in vivo.
  8. BRD9 BD Inhibitor

    BI-7273 is a selective, and cell-permeable BRD9 BD inhibitor.
  9. BRD4 inhibitor

    OXF BD 02, selective inhibitor of the first bromodomain of BRD4 (BRD4(1)) (IC50 = 382 nM). Exhibits 2-3-fold selectivity for BRD4(1) over the CBP bromodomain and has little affinity for a range of other bromodomains.
  10. BRD4 inhibitor

    ZL0420 is a potent and selective BRD4 inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2 respectively and good selectivity over that of the related BRD2 homolog.
  11. p300/CBP inhibitor

    A-485 is a potent and selective HAT inhibitor of p300/CBP in vitro with an IC50 of 10 nM in a p300 TR-FRET assay and 3 nM in a CBP TR-FRET assay with selectivity > 1000-fold over closely related HATs.
  12. BRD4 Inhibitor

    ARV-825 is a hetero-bifunctional molecule that is composed of a BRD4 binding moiety joined to an E3 ligase cereblon binding moiety using proteolysis targeting chimera (PROTAC) technology.
  13. CBP/beta-catenin modulator

    E-7386 is an orally active CBP/beta-catenin modulator.
  14. selective CREB inhibitor

    666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM.
  15. selective BET inhibitor

    PLX51107 is a potent and selective BET inhibitor, with Kds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (Kd, in the 100 nM range).
  16. BET inhibitor

    (S)-JQ-35 (TEN-010) is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity.
  17. BRD4-degrading PROTAC

    A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation.
  18. BRD inhibitor

    BETd-246 is a second-generation BET bromodomain (BRD) inhibitor, exhibiting superior selectivity, potency and antitumor activity.
  19. BRD4BD1degrader

    dBET57 is a potent and selective degrader of BRD4BD1 based on the PROTAC technology.
  20. BET bromodomain inhibitor

    (+)-JQ1 PA is a clickable JQ1 for building PROTACs, which acts as a BET bromodomain inhibitor.
  21. BRD3/4 degrader

    MZP-55 is a selective degrader of BRD3/4 based on PROTAC technology, with a Kd of 8 nM for Brd4BD2.
  22. BRD3/4 degrader

    MZP-54 is a selective degrader of BRD3/4 based on PROTAC technology, with a Kd of 4 nM for Brd4BD2.
  23. BET inhibitor

    INCB-057643 is a novel, orally bioavailable BET inhibitor.
  24. BET inhibitor

    BET bromodomain inhibitor is a potent BET inhibitor extracted from patent WO/2015/153871A2, compound example 11.
  25. BET degrader

    dBET6 is a highly potent, selective and cell-permeable degrader of BET based on PROTAC, with an IC50 of 14 nM, and has antitumor activity.
  26. BRD4 inhibitor

    ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.
  27. Menin-MLL Inhibitor

    MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.
  28. BET inhibitor

    (Rac)-BAY1238097 is a BET inhibitor, with an IC50 of 1.02 μM for BRD4. Used in cancer research.
  29. BET/BRD4 bromodomain inhibitor

    AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM.
  30. L3MBTL domain inhibitor

    UNC-669 is a L3MBTL domain inhibitor.
  31. Phoenixin-20 (PNX-20) is a bioactive peptide with hormone-like actions in vertebrates, and can stimulates hypothalamo-pituitary-gonadal hormones and regulate reproductive processes in mammals. Phoenixin-20 promotes neuronal mitochondrial biogenesis via CREB-PGC-1α pathway. Phoenixin-20 has anxiolytic effect.

31 Items

per page
Set Descending Direction